Los Angeles Business Journal


Recent and archived news stories on: Biotechnology, Doctors, Drugs, Health Insurance, HMO's/PPO's, Hospitals, Medical Devices, Nursing...

Soon-Shiong’s NantHealth Raises $250 Million From Kuwait Fund

NantHealth, the health care technology division of billionaire Patrick Soon-Shiong’s Culver City holding company NantWorks LLC, said Wednesday it has raised $250 million in additional funding from the Kuwait Investment Authority.

Amgen Seeks Approval for Leukemia Drug

Amgen Inc. announced on Monday that it is seeking regulatory approval to sell a drug for treating a rare and particularly deadly form of leukemia.

Kite Pharma Stock Surges After Cancer Study Announcement

Shares of Santa Monica’s Kite Pharma surged nearly 30 percent in after-hours trading Monday after the clinical-stage biotech company announced the publication of clinical results demonstrating the potential of its KTE-C19 drug to treat aggressive non-Hodgkin's lymphoma

Second Sight Prepares IPO

Second Sight, a Sylmar company founded by billionaire Alfred Mann to develop an artificial retina for blind patients, filed paperwork for an initial public offering on Tuesday.

Torrance Memorial Medical Center, USC Have New Affiliation

A new affiliation between Torrance Memorial Medical Center and USC Keck School of Medicine is expected to increase the former’s ability to provide heart surgery services.

L.A. Billionaire Now With Providence Health

L.A. billionaire and biotech entrepreneur Dr. Patrick Soon-Shiong will become the global director for cancer services and bioinformatics at Providence Health & Services, the hospital chain announced on Thursday.

Molina Net Income Falls Short

Molina Healthcare Inc. reported meager earnings after markets closed Wednesday, falling well short of Wall Street expectations on profits.

USC’s Keck Acquires OC-Based Practice for Cancer Network

Keck Medicine of USC, the University of Southern California’s medical enterprise, has acquired Orange Coast Oncology Hematology Medical Associates for an undisclosed price as part of a cancer-treatment network allowing local patients to avoid trips to Los Angeles for care.

Amgen Lung-Cancer Drug Goes to Trial

Amgen Inc. announced on Monday it is joining a high-level research partnership that will test its experimental cancer drug rilotumumab on lung-cancer patients.

MannKind in Talks for Afrezza Partnership

Diabetes drug developer MannKind Corp. of Valencia is exploring multiple partnership opportunities to take its inhalable insulin drug Afrezza to market as the company awaits FDA approval.

New Amgen CFO Gets $2 Million Signing Bonus

Amgen Inc. appointed David W. Meline as its chief financial officer on Monday, luring him from 3M with a $2 million signing bonus.

Puma Shares Fall Amid Trial Results

Shares of Westwood drug developer Puma Biotechnology plummeted in trading on Monday after presentations by the company and another drugmaker soured investors on their prospects.

Samsung Vs. Amgen in Arthritis Market

Samsung Group, the largest company in South Korea, plans to enter the drug trade by competing directly with Amgen Inc. in Thousand Oaks.

MannKind Narrows Loss, Awaits FDA's Decision

MannKind Inc. reported a smaller loss for the first quarter on Monday as it awaits government approval to sell its brand of inhalable insulin.

IPC Makes Texas Acquisition

IPC The Hospitalist Co. Inc. is acquiring Total Inpatient Services in Sugar Land, Texas.